Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: Adpt | Vintage Vibes

Adaptive Biotechnologies Stock Has Doubled in the Past Year. Here’s What Could Come Next.

Adaptive Biotechnologies (ADPT) has surged 100% over the past year, driven by strong technical momentum. Shares recently hit a new 3-year high. Analyst sentiment is mixed with price targets ranging from $17 to $30. Investor focus has shifted from ADPT’s technology to its business execution, with technical indicators and momentum...

Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference

Adaptive Biotechnologies (NASDAQ:ADPT) Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted partnerships for its Immune Medicine platform, during a presentation at William Blair’s Growth Stoc

Can This Red-Hot Biotech Stock Live Up to Wall Street’s Expectations?

Can This Red-Hot Biotech Stock Live Up to Wall Street’s Expectations?

Adaptive Biotechnologies (ADPT) is a commercial-stage biotech with strong technical momentum. Shares are up 250% in the past year and just hit a new three-year high. ADPT maintains a 100% “Buy” opinion from Barchart, a Trend Seeker “Buy” signal, and robust technical indicators. Fundamentals show projected revenue and earnings growth,...

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics

On Friday, Cathie Wood-led Ark Invest made significant trades in the market, with the most prominent ones being in Veracyte Inc. (NASDAQ:VCYT), Iridium Communications Inc. (NASDAQ:IRDM), CRISPR Therapeutics AG (NASDAQ:CRSP), Kratos Defense Security Solutions Inc. (NASDAQ:KTOS), Absci Corp. (NASDAQ:ABSI), Veeva Systems Inc. (NYSE:VEEV), Adaptive Biotechnologies Corp. (NASDAQ:ADPT) and Guardant Health…

Is Bio-Techne Corporation Stock Underperforming the S&P 500?

Despite Bio-Techne Corporation’s underperformance relative to the S&P 500 over the past year, analysts maintain a bullish outlook on the stock’s prospects.

Adaptive Biotechnologies To Lay Off ~12% Of Its Workforce, Names Tycho Peterson As CFO

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) will be organized around two distinct business areas - Minimal Residual Disease (MRD) and Immune Medicine.

Adaptive Biotechnologies Clocks 26% Jump In Q4 Revenues

Adaptive Biotechnologies Corp (NASDAQ: ADPT)

inkl

Read news from The Economist, FT, and more,
with one subscription

Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed

Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed

Adaptive Biotechnologies (NASDAQ:ADPT) brought in sales totaling $37.93 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 9.57%, resulting in a loss of $61.36 million.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Veeva Systems Inc

Adaptive Biotechnologies

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

418,696 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play